B

Beijing Winsunny Pharmaceutical Co Ltd
SSE:601089

Watchlist Manager
Beijing Winsunny Pharmaceutical Co Ltd
SSE:601089
Watchlist
Price: 28.9 CNY 6.09%
Market Cap: ¥5.5B

Relative Value

The Relative Value of one Beijing Winsunny Pharmaceutical Co Ltd stock under the Base Case scenario is 22.87 CNY. Compared to the current market price of 28.9 CNY, Beijing Winsunny Pharmaceutical Co Ltd is Overvalued by 21%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
22.87 CNY
Overvaluation 21%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Beijing Winsunny Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Beijing Winsunny Pharmaceutical Co Ltd
SSE:601089
5.5B CNY 1.6 11.8 11 11
US
Eli Lilly and Co
NYSE:LLY
978.7B USD 16.5 53.2 35.7 38.3
US
Johnson & Johnson
NYSE:JNJ
547.3B USD 5.8 20.4 14.2 17.5
CH
Roche Holding AG
SIX:ROG
277.3B CHF 4.5 29.4 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
210B GBP 4.9 30.2 19.7 28.8
CH
Novartis AG
SIX:NOVN
220.8B CHF 5 19.4 15.5 20
US
Merck & Co Inc
NYSE:MRK
273B USD 4.3 14.4 10.2 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.8 11 12.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
150.2B USD 2.4 15.3 7.7 10.5
FR
Sanofi SA
PAR:SAN
95.7B EUR 1.7 8 7.6 7.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
B
Beijing Winsunny Pharmaceutical Co Ltd
SSE:601089
Average EV/EBITDA: 44.6
11
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.7
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.2
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
CH
Novartis AG
SIX:NOVN
15.5
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
7.6
8%
0.9